Pharmacological modulation of the natriuretic peptide system

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 9, 2003, Pages 1389-1409

  Venugopal, Joshi ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Atrial natriuretic peptide (ANP); Brain natriuretic peptide (BNP); C type natriuretic peptide (CNP); Dendroaspis natriuretic peptide (DNP); Hypertension; Myocardial infarction; Natriuretic; Neutral endopeptidase; Plasminogen activator inhibitor; Urodilain; Vasoendopeptidase

Indexed keywords

7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ATRIOPEPTIN III [106 DEPHENYLALANINE 107 DEGLYCINE 115 DEALANINE 116 DEGLUTAMINE]; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA LACTAM DERIVATIVE; BRADYKININ; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; ENALAPRILAT; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; FASIDOTRIL; FASIDOTRILAT; FOSINOPRIL; GEMOPATRILAT; GLYCERYL TRINITRATE; LIGAND; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; NESIRITIDE; OMAPATRILAT; RECOMBINANT HORMONE; SAMPATRILAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URODILATIN; VANCOMYCIN; VASOPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIURETIC ACTIVITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG RESEARCH; ENZYME INHIBITION; FATIGUE; FIRST PASS EFFECT; HEART ARRHYTHMIA; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOTENSION; INOTROPISM; KIDNEY FAILURE; LIVER FAILURE; NAUSEA; NONHUMAN; PATENT; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; VERTIGO;

EID: 0141628437     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.9.1389     Document Type: Review

References (143)

1. DE BOLD AJ: Heart atrial granularity: effects of changes in water-electrolyte balance. Proc. Soc. Exp. Biel. Med. (1979) 161:508-511.
2. VENUGOPAL J: Cardiac natriuretic peptides-hope or hype? J. Clin. Pharm. Ther. (2001) 26:15-31.
3. RUSKOAHO H: Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol. Rev. (1992) 44:479-602.
4. SCHIRGER JA, HEUBLEIN DM, CHEN HH et al.: Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo. Clin. Proc. (1999) 74:126-130.
5. TAKEI Y: Does the natriuretic peptide system exist throughout the animal and plant kingdom? Comp. Biochem. Physiol. B Biochem. Mol. Biol. (2001) 129:559-573.
6. MURTHY KS, TENG BQ, ZHOU H, JIN JG, GRIDER JR, MAKHLOUF GM: G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am. J. Physiol. Gastrointest. Liver Physiol. (2000) 278:G974-G980.
7. GOY MF, OLIVER PM, PURDY KE et al.: Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide. Biochem. J. (2001) 358:379-387.
8. SUGA S, NAKAO K, HOSODA K et al.: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology (1992) 130:229-239.
9. CHINKERS M, GARBERS DL, CHANG MS et al.: A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature (1989) 338:78-83.
10. POTTER LR, HUNTER T: Phosphorylation of the kinase homology domain is essential for activation of the A-type natriuretic peptide receptor. Mol. Cell. Biol. (1998) 18:2164-2172.
11. POTTER LR, HUNTER T: Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor. J. Biol. Chem. (1998) 273:15533-15539.
12. BRYAN PM, POTTER LR: The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases. J. Biol. Chem. (2002) 3:16041-16047.
13. FOSTER DC, GARBERS DL: Dual role for adenine nucleotides in the regulation of the atrial natriuretic peptide receptor, guanylyl cyclase-A. J. Biol. Chem. (1998) 273:16311-16318.
14. ITAKURA M, SUZUKI H, HIROSE S: Structural analysis of natriuretic peptide receptor-C by truncation and site-directed mutagenesis. Biochem. J. (1997) 322(Pt2):585-590.
15. CHAUHAN SD, NILSSON H, AHLUWALIA A, HOBBS AJ: Release of C-type natriuretic peptide accounts for the biological activity ofendothelium-derived hyperpolarizing factor. Proc. Natl. Acad. Sci. USA (2003) 100:1426-1431.
16. LEANEY JL, TINKER A: The role of members of the pertussis toxin-sensitive family of G proteins in coupling receptors to the activation of the G-protein-gated inwardly rectifying potassium channel. Proc. Natl. Acad. Sci. USA (2000) 97:5651-5656.
17. 2+-independent protein kinase C. J. Physiol. (2001) 534:367-379.
18. VAN DEN AKKER F, ZHANG X, MIYAGI M, HUO X, MISONO KS, YEE VC: Structure of the dimerized hormone-binding domain of a guanylylcyclase-coupled receptor. Nature (2000) 406:101-104.
19. MISONO KS: Atrial natriuretic factor binding to its receptor is dependent on chloride concentration: a possible feedback-control mechanism in renal salt regulation. Circ. Res. (2000) 86:1135-1139.
20. KISCH B: Electron microscopy of the atrium of the heart in guinea-pig. Exp. Med. Surg. (1956) 14:99-112.
21. DE BOLD AJ: Atrial natriuretic factor of the rat heart. Studies on isolation and properties. Proc. Soc. Exp. Biol. Med. (1982) 170:133-138.
22. SUDOH T, KANGAWA K, MINAMINO N, MATSUO H: A new natriuretic peptide in porcine brain. Nature (1988) 332:78-81.
23. SUDOH T, MINAMINO N, KANGAWA K, MATSUO H: C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. (1990) 168:863-870.
24. SCHULZ-KNAPPE P, FORSSMANN K, HERBST F, HOCK D, PIPKORN R, FORSSMANN WG: Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin. Wochenschr. (1988) 66:752-759.
25. SCHWEITZ H, VIGNE P, MOINIER D, FRELIN C, LAZDUNSKI M: A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. (1992) 267:13928-13932.
26. FERNANDEZ-DURANGO R, TRIVINO A, RAMIREZ JM et al.: Immunoreactive atrial natriuretic factor in aqueous humor: its concentration is increased with high intraocular pressure in rabbit eyes. Vision Res. (1990) 30:1305-1310.
27. ITOH H, SAGAWA N, HASEGAWA M et al.: Transforming growth factor-β stimulates, and glucocorticoids and epidermal growth factor inhibit brain natriuretic peptide secretion from cultured human amnion cells. J. Clin. Endocrinol. Metab. (1994) 79:176-182.
28. CHRISMAN TD, SCHULZ S, POTTER LR, GARBERS DL: Seminal plasma factors that cause large elevations in cellular cyclic GMP are C-type natriuretic peptides. J. Biol. Chem. (1993) 268:3698-3703.
29. HUANG H, ACUFF CG, STEINHELPER ME: Isolation, mapping, and regulated expression of the gene encoding mouse C-type natriuretic peptide. Am. J. Physiol. (1996) 271:H1565-1575.
30. 2+-ATPase gene. Circ. Res. (1992) 71:9-17.
31. VOLLMAR AM, GERBES AL, NEMER M, SCHULZ R: Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology (1993) 132:1872-1874.
32. KINOSHITA H, FUJIMOTO S, FUKAE H et al.: Plasma and urine levels of uroguanylin, a new natriuretic peptide, in nephrotic syndrome. Nephron (1999) 81:160-164.
33. SAHAI A, GANGULY PK: Atrial natriuretic peptide: pathophysiological considerations. Indian J. Physiol. Pharmacol. (1992) 36:3-14.
34. KENNY AJ, BOURNE A, INGRAM J: Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biachem. J. (1993) 291 (Pt 1):83-88.
35. QIU WQ, WALSH DM, YE Z et al.: Insulin-degrading enzyme regulates extracellular levels of amyloid-β-protein by degradation. J. Biol. Chem. (1998) 273:32730-32738.
36. NUSSENZVEIG DR, LEWICKI JA, MAACK T: Cellular mechanisms of the clearance function of type-C receptors of atrial natriuretic factor. J. Biol. Chem. (1990) 265:20952-20958.
37. HE X, CHOW D, MARTICK MM, GARCIA KC: Allosteric activation of a spring-loaded natriuretic peptide receptor dimer by hormone. Science (2001) 293:1657-1662.
38. UNGER T, BADOER E, GAREIS C et al.: Atrial natriuretic peptide (ANP) as a neuropeptide: interaction with angiotensin II on volume control and renal sodium handling. Br. J. Clin. Pharmacol. (1990) 30(Suppl.):83S-88S.
39. CARON N, KRAMP R: Measurement of changes in glomerular filtration rate induced by atrial natriuretic peptide in the rat kidney. Exp. Physiol. (1999) 84:689-696.
40. CLEMO HF, BAUMGARTEN CM: Atrial natriuretic factor decreases cell volume of rabbit atrial and ventricular myocytes. Am. J. Physiol. (1991) 260:C681-C690.
41. HIROSE M, FURUKAWA Y, KUROGOUCHI F, NAKAJIMA K, MIYASHITA Y, CHIBA S: C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. J. Pharmacol. Exp. Ther. (1998) 286:70-76.
42. ROSENKRANZ AC, WOODS RL, DUSTING GJ, RITCHIE RH: Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc. Res. (2003) 57:515-522.
43. QIAN JY, HARUNO A, ASADA Y et al.: Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ. Res. (2002) 91:1063-1069.
44. YAMAHARA K, ITOH H, CHUN TH et al.: Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc. Natl. Acad. Sci. USA (2003) 100:3404-3409.
45. WIECZOREK SJ, WU AH, CHRISTENSON R et al.: A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am. Heart J. (2002) 144:834-839.
46. FAHEY MT, IRWIG L, MACASKILL P: Meta-analysis of Pap test accuracy. Am. J. Epidemiol. (1995) 141:680-689.
47. JACOBSEN SJ, BERGSTRALH EJ, GUESS HA et al.: Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch. Intern. Med.(1996) 156:2462-2468.
48. PAWLOWSKA Z, JERCZYNSKA H, SZEMRAJ J, BARANSKA P, SWIATKOWSKA M, CIERNIEWSKI CS: Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell. Mol. Biol. Lett. (2002) 7:1153-1157.
49. PEDRAM A, RAZANDI M, LEVIN ER: Natriuretic peptides suppress vascular endothelial cell growth factor signaling to angiogenesis. Endocrinology (2001) 142:1578-1586.
50. ITO T, YOSHIMURA M, NAKAMURA S et al.: Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation (2003) 107:807-810.
51. ABRAHAM WT, LOWES BD, FERGUSON DA et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail. (1998) 4:37-44.
52. ARONSON D, BURGER AJ: Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am. J. Cardiol. (2002) 90:435-438.
53. PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS: Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 287:1531-1540.
54. BURGER AJ, HORTON DP, LEJEMTEL T et al.: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. (2002) 144:1102-1108.
55. MUROHARA T, KUGIYAMA K, YASUE H: Interactions of nitrovasodilators, atrial natriuretic peptide and endothelium-derived nitric oxide. J. Vasc. Res. (1996) 33:78-85.
56. CEDIDI C, KUSE ER, MEYER M et al.: Treatment of acute postoperative renal failure after liver and heart transplantation by urodilatin. Clin. Investig. (1993) 71:435-436.
57. WIEBE K, MEYER M, WAHLERS T et al.: Acute renal failure following cardiac surgery is reverted by administration of Urodilatin (INN: Ularitide ) Eur. J. Med. Res.(1996) 1:259-265.
58. HUMMEL M, KUHN M, BUB A et al.: Urodilatin, a new therapy to prevent kidney failure after heart transplantation. J. Heart Lung Transplant. (1993) 12:209-217; discussion 217-208.
59. BRENNER P, MEYER M, REICHENSPURNER H et al.: Significance of prophylactic urodilatin (INN: ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation. Eur. J. Med. Res. (1995) 1:137-143.
60. MEYER M, PFARR E, SCHIRMER G et al.: Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren. Fail. (1999) 21:85-100.
61. ANDREASSI MG, DEL RY S, PALMIERI C, CLERICO A, BIAGINI A, GIANNESSI D: Up-regulation of 'clearance' receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur. J. Heart Fail. (2001) 3:407-414.
62. OKOLICANY J, MCENROE GA, GREGORY LC, LEWICKI JA, MAACK T: Effects of small C-ANF receptor ligands on plasma levels of atrial natriuretic factor, blood pressure, and renal function in the rat. Can. J. Physiol. Pharmacol. (1991) 69:1561-1566.
63. BRALET J, SCHWARTZ JC: Vasopeptidase inhibitors: an emerging class of cardiovascular drugs. Trends Pharmacol. Sci. (2001) 22:106-109.
64. ENNEZAT PV, BERLOWITZ M, SONNENBLICK EH, LE JEMTEL TH: Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr. Cardiol. Rep. (2000) 2:258-262.
65. JORDE UP, ENNEZAT PV, LISKER J, SURYADEVARA V et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 101:844-846.
66. VAN DEN MEIRACKER AH, MAN IN 'T VELD AJ, ADMIRAAL PJ et al.: Partial escape of angiotensin-converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J. Hypertens. (1992) 10:803-812.
67. NAKAMURA M, ARAKAWA N, YOSHIDA H, MAKITA S, NIINUMA H, HIRAMORI K: Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am. Heart J. (1998) 135:414-420.
68. FIELITZ J, DENDORFER A, PREGLA R et al.: Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation (2002) 105:286-289.
69. OEFNER C, D'ARCY A, HENNIG M, WINKLER FK, DALE GE: Structure of human neutral endopeptidase (neprilysin) complexed with phosphoramidon. J. Mol. Biol. (2000) 296:341-349.
70. SKIDGEL RA, ERDOS EG: Cellular carboxypeptidases. Immunol. Rev. (1998) 161:129-141.
71. ERDOS EG, SKIDGEL RA: Neutral endopeptidase 24.11 (enkephatinase) and related regulators of peptide hormones. FASEB J. (1989) 3:145-151.
72. SANI M: Vasopeptidase inhibitor: an emerging class of cardiovascular drugs. Hospital Pharmacy (2001) 8:280-282.
73. TABRIZCHI R: Omapatrilat. Bristol-Myers Squibb. Curr. Opin. Investig. Drugs (2001) 2:1414-1422.
74. TRIPPODO NC, FOX M, MONTICELLO TM, PANCHAL BC, ASAAD MM: Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J. Cardiovasc. Pharmacol. (1999) 34:782-790.
75. LAPOINTE N, NGUYEN QT, DESJARDINS JF et al.: The effects of preperi- and post-myocardial infarction treatment with omapatrilat in rats: effects on survival, arrhythmias, function and remodelling. Am. J. Physiol. Heart Circ. Physiol. (2003).
76. QUASCHNING T, D'USCIO LV, SHAW S, LUSCHER TF: Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension (2001) 37:1108-1113.
77. MILLETTE E, DEMEILLIERS B, WU R et al.: Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. J. Hypertens. (2003) 21:125-135.
78. RODRIGUEZ-GOMEZ I, WANGENSTEEN R, ATUCHA NM et al.: Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats. Am. J. Hypertens. (2003) 16:33-38.
79. BACKLUND T, PALOJOKI E, SARASTE A et al.: Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc. Res. (2003) 57:727-737.
80. DONG Y, ZHOU H, SHAFFER E, ATAMAS N, LIAO WC, WEI C: The cardiovascular actions of omapatrilat in spontaneously hypertensive rats. Curr. Hypertens. Rep. (2001) 3(Suppl.2):S1-5.
81. LAPOINTE N, BLAIS C Jr, ADAM A et al.: Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J. Am. Coll. Cardiol. (2002) 39:1692-1698.
82. ARNAL JF, CASTANO C, MAUPAS E et al.: Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis (2001) 155:291-295.
83. THOMAS CV, MCDANIEL GM, HOLZGREFE HH et al.: Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J. Cardiovasc. Pharmacol. (1998) 32:902-912.
84. MANIU CV, MEYER DM, REDFIELD MM: Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension. Hypertension (2002) 40:528-534.
85. TROUGHTON RW, RADEMAKER MT, POWELL JD et al.: Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension (2000) 36:523-530.
86. WANG CH, LEUNG N, LAPOINTE N et al.: Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II Type I receptor blocker. Circulation (2003) 107:1923-1929.
87. MASSIEN C, AZIZI M, GUYENE TT, VESTERQVIST O, MANGOLD B, MENARD J: Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin. Pharmacol. Ther. (1999) 65:448-459.
88. AZIZI M, LAMARRE-CLICHE M, LABATIDE-ALANORE A, BISSERY A, GUYENE TT, MENARD J: Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. J. Am. Soc. Nephrol (2002) 13:2454-2463.
89. LIAO CLD, CATANZARITI PA, MEIER A, SWANSON BN, UDERMAN HD: Omapatrilat is not a diuretic: single- and multiple-dose analysis of the urinary excretion of sodium. Am J. Hypertens. (2000) 13:S-113.
90. COATS AJ: Omapatrilat-the story of OVERTURE and OCTAVE. Int. J. Cardiol. (2002) 86:1-4.
91. ROULEAU JL, PFEFFER MA, STEWART DJ et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 356:615-620.
92. PACKER M, CALIFF RM, KONSTAM MA et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation (2002) 106:920-926.
93. KUOPPALA A, SHIOTA N, KOKKONEN JO et al.: Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure. J. Am. Coll. Cardiol. (2002) 40:119-125.
94. PRADO GN, TAYLOR L, ZHOU X, RICUPERO D, MIERKE DF, POLGAR P: Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J. Cell. Physiol. (2002) 193:275-286.
95. WALLIS EJ, RAMSAY LE, HETTIARACHCHI J: Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin. Pharmacol. Ther. (1998) 64:439-449.
96. NORTON GR, WOODIWISS AJ, HARTFORD C et al.: Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am. J. Hypertens. (1999) 12:563-571.
97. MAKI T, NASA Y, TANONAKA K, TAKAHASHI M, TAKEO S: Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J. Pharmacol. Exp. Ther. (2003) 305:97-105.
98. ROBL J, RYONO D: Recent advances in the design and development of vasopeptidase inhibitors. Exp. Opin. Ther. Patents (1999) 9:1665-1677.
99. LAURENT S, BOUTOUYRIE P, AZIZI M et al.: Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension (2000) 35:1148-1153.
100. MARIE C, MOSSIAT C, LECOMTE JM et al.: Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. J. Pharmacol. Exp. Ther. (1995) 275:1324-1331.
101. BRALET J, MARIE C, MOSSIAT C, LECOMTE JM, GROS C, SCHWARTZ JC: Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. J. Pharmacol. Exp. Ther. (1994) 270:8-14.
102. MONTEIL T, DANVY D, SIHEL M, LEROUX R, PLAQUEVENT JC: Strategies for access to enantiomerically pure ecadotril, dexecadotril and fasidotril: a review. Mini Rev. Med. Chem. (2002) 2:209-217.
103. HUBNER RA, KUBOTA E, CASLEY DJ, JOHNSTON CI, BURRELL LM: In vitro and in vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. J. Hypertens. (2001) 19:941-946.
104. TRIPPODO NC, ROBL JA, ASAAD MM, FOX M, PANCHAL BC, SCHAEFFER TR: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J. Hypertens. (1998) 11:363-372.
105. FRENCH JF, FLYNN GA, GIROUX EL et al.: Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase. J. Pharmacol. Exp. Ther. (1994) 268:180-186.
106. ROUSSO P, BUCLIN T, NUSSBERGER J, BRUNNER-FERBER F, BRUNNER HR, BIOLLAZ J: Bioavailability of repeated oral administration of MDL-100240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers. Eur. J. Clin. Pharmacol. (2000) 55:749-754.
107. GARDINER SM, KEMP PA, BRUNNER-FERBER F, BENNETT T: Effects of the dual metallopeptidase inhibitor, MDL-100240, on regional haemodynamic responses to vasoactive peptides in conscious rats. Br. J. Pharmacol. (1997) 122:1687-1693.
108. ROUSSO P, BUCLIN T, NUSSBERGER J, BRUNNER-FERBER F, BRUNNER HR, BIOLLAZ J: Effects of MDL-100240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers. J. Cardiovasc. Pharmacol. (1998) 31:408-417.
109. GARDINER SM, KEMP PA, BRUNNER-FERBER F, BENNETT T: Comparative effects of the dual metallopeptidase inhibitor, MDL-100240 and of enalaprilat on regional and on cardiac haemodynamics in conscious, hypertensive, transgenic ((mRen-2)27) rats. Br. J. Pharmacol. (1997) 122:1694-1701.
110. ROSSI GP, BOVA S, SACCHETTO A: Comparative effects of the dual ACE-NEP inhibitor MDL-100240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension. Am J. Hypertens. (2002) 15:181-188.
111. ROSSI GP, CAVALLIN M, RIZZONI D et al.: Dual ACE and NEP inhibitor MDL-100240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin Type 2 receptor. J. Hypertens. (2002) 20:1451-1459.
112. WECKLER N: Effects of a chronic treatment with the ACE NEP inhibitor AVE-7688 and ramipril on the endotheliale dysfunktion at the model of the atherogen fed rabbit. PhD thesis (Justus Liebig university pouring, Germany) (2002)
113. GONZALEZ VERA W, FOURNIE-ZALUSKI MC, PHAM I, LABOULANDINE I, ROQUES BP, MICHEL JB: Hypotensive and natriuretic effects of RB-105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J. Pharmacol. Exp. Ther. (1995) 272:343-351.
114. FOURNIE-ZALUSKI MC, GONZALEZ W, TURCAUD S, PHAM I, ROQUES BP, MICHEL JB: Dual inhibition of anglotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc. Natl. Acad. Sci. USA (1994) 91:4072-4076.
115. BALKAU B, ESCHWEGE E, PAPOZ L et al.: Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. Br. Med. J. (1993) 307:295-299.
116. ARBIN V, CLAPERON N, FOURNIE-ZALUSKI MC, ROQUES BP, PEYROUX J: Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br. J. Pharmacol. (2001) 133:495-502.
117. SHIUCHI T, CUI TX, WU L et al.: ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension (2002) 40:329-334.
118. KIRPICHNIKOV D, SOWERS JR: Role of ACE inhibitors in treating hypertensive diabetic patients. Curr. Diab. Rep. (2002) 2:251-257.
119. ARBIN V, CLAPERON N, FOURNIE-ZALUSKI MC, ROQUES BP, PEYROUX J: Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese zucker rats. J. Cardiovasc. Pharmacol. (2003) 41:254-264.
120. LASSILA M, DAVIS BJ, ALLEN TJ, BURRELL LM, COOPER ME, CAO Z: Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin. Sci. (London) (2003) 104:341-347.
121. FARINA NK, JOHNSTON CI, BURRELL LM: Reversal of cardiac hypertrophy and fibrosis by S-21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J. Hypertens. (2000) 18:749-755.
122. MORAZZONI G, ALLIEVI L, BRANCA E: In vitro and ex vivo characterisation of Z-13752A, a new dual-acting ACE/N EP inhibitor. Eur. J. Pharmacol. Sci. (1998) 6.
123. BANI M, COLANTONI A, GUILLAUME M, MACCHI F, MORONI G, PERSIANI S: A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z-13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers. Br. J. Clin. Pharmacol. (2000) 50:338-349.
124. RASTEGAR MA, MARCHINI F, MORAZZONI G, VEGH A, PAPP JG, PARRATT JR: The effects of Z-13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br. J. Pharmacol. (2000) 129:671-680.
125. BHAGWATT S, FINK C, GUDE C: α-Mercaptoacyl dipeptides that inhibit angiotensin conveting enzyme and nuetral endopeptidase 24.11. Bioorg. Med. Chem. lett. (1995) 5:735-738.
126. FINK CA, QIAO Y, BERRY CJ, SAKANE Y, GHAI RD, TRAPANI AJ: New α-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. J. Med. Chem. (1995) 38:5023-5030.
127. COHEN D, FINK C, TRAPANI A, WEBB R, ZANE P, CHATELAIN R: CGS-30440: a dual inhibitor of angiotensin converting enzyme and nuetral endopeptidase 24.11. Cardiovasc. Drug Rev. (1999) 17:16-38.
128. ICHINOSE F, ADRIE C, HURFORD WE, BLOCH KD, ZAPOL WM: Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology (1998) 88:410-416.
129. NAGAMINE J, HILL LL, PEARL RG: Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit. Care Med. (2000) 28:2420-2424.
130. WEIMANN J, ULLRICH R, HROMI J et al.: Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology (2000) 92:1702-1712.
131. KIM D, RYBALKIN SD, PI X et al.: Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation (2001) 104:2338-2343.
132. MULSCH A, OELZE M, KLOSS S et al.: Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation (2001) 103:2188-2194.
133. SUPAPORN T, SANDBERG SM, BORGESON DD et al.: Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. (1996) 50:1718-1725.
134. VENUGOPAL J, BOYLE N, KELLY J: Identification of the expression of inhibitory γ subunit of phosphodiesterase-6 in non-retinal murine tissues. Curr. Sci. (2003) 84:1227-1231.
135. MOVSESIAN MA: Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opin. Investig. Drugs (2000) 9:963-973.
136. BURT VL, CUTLER JA, HIGGINS M et al.: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension (1995) 26:60-69.
137. CAMPESE VM, LASSETER KC, FERRARIO CM et al.: Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension (2001) 38:1342-1348.
138. FERDINAND K, SAINI R, LEWIN A, YELLEN L, BARBOSA JA, KUSHNIR E: Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. Am. J. Hypertens. (2001) 14:788-793.
139. TRIPPODO NC, PANCHAL BC, FOX M: Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J. Pharmacol. Exp. Ther. (1995) 272:619-627.
140. YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411-415.
141. BRUTSAERT DL: Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol. Rev. (2003) 83:59-115.
142. PERALTA C, BULBENA O, BARGALLO R, PRATS N, GELPI E, ROSELLO-CATAFAU J: Strategies to modulate the deleterious effects of endothelin in hepatic ischemia-reperfusion. Transplantation (2000) 70:1761-1770.
143. MATSUKAWA N, GRZESIK WJ, TAKAHASHI N et al.: The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl. Acad. Sci. USA (1999) 96:7403-7408.